A few days ago, some scholars engaged in medical investment and genomic medical research discussed the technology robbery in industrial development at the " Gene Sequencing Track Scanning Salon" and hoped to clarify the "road map" of industrial development.

In March 2016, in the relevant notices of the key special application guidelines issued by the Ministry of Science and Technology, “Precision Medical Research” was listed as one of the priority projects launched in 2016, supporting the precision medical industry based on gene sequencing.

From the short-term clinical stoppage of gene sequencing in 2014 by the Health Planning Commission, to the launch of the pilot list in the same year, the policy was restarted, and the “generating train to the spring” of the genetic sequencing industry in China was started.

Over a year since the pilot, relevant industries, enterprises and research units have found their way to quickly start the registration of related instruments, reagents and software, and have led to research focus and capital accumulation.

Read the "secondary password" to get on the line with "illness"

From research to clinical, the biggest obstacle is that the problem of money has been solved. What else is “robbery”?

Compared with the publication of the 2001 human genome sketch, the cost of gene sequencing has dropped to “one in ten thousand”, but the clinical application has not multiplied.

In fact, "sequencing" only completes the interpretation of the "first-level password" of the living body. To associate it with the disease, it is also necessary to "decipher" which diseases caused by the mutation of the gene, and the "gene fragments" and "diseases" Match it and complete the deciphering of the “secondary password”.

The Ph.D. tutor of the Beijing Institute of Genomics of the Chinese Academy of Sciences has summarized the clinical application into three elements: the cohort and the sample library are the foundation, the medical intervention is the core, and the data integration and analysis are the key.

Therefore, the single gene sequencing data can not guide the clinical treatment. To learn the "secondary codebook", it is necessary to establish a sample library, accumulate multi-dimensional data and analyze it, and peel off the "life code" layer by layer to guide clinical treatment.

"It is the ability to interpret genetic data and multi-dimensional data, and push gene sequencing technology into clinical diagnosis and treatment."

However, the current ability to analyze and interpret genetic data is still insufficient. The interpretation of genetic data remains largely at the genetic level, rather than the precise level of gene mutation. At the same time, the genetic data cannot be compared with the patient's physical signs, living habits, and microscopic. Comprehensive analysis of multi-dimensional data such as the environment.

Supplier Extract Powder

We're Professional Supplier Extract Powder manufacturers and suppliers in China specialized in providing high-quality products at low price. We warmly welcome you to buy or wholesale bulk Supplier Extract Powder for sale here from our factory. For a free sample, contact us now.


Supplier Extract Powder,Supplier Extract ,Supplier Powder Manufacturer in China

Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.anabolicsteriod.com